Drug Profile
Research programme: infectious diseases therapeutics - GlaxoSmithKline
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Leishmaniasis; Malaria; Trypanosomiasis; Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Leishmaniasis in Spain
- 16 Jul 2016 No recent reports of development identified for research development in Malaria in Spain
- 16 Jul 2016 No recent reports of development identified for research development in Trypanosomiasis in Spain